Skip to main content
Premium Trial:

Request an Annual Quote

For Early-Stage Patients

The US Food and Drug Administration has narrowed the group of patients who could receive a controversial Alzheimer's disease drug, the Washington Post says.

The FDA approved aducanumab, Biogen's Aduhelm, in June, a decision that drew criticism and sparked resignations from an FDA advisory board. The board had voted in November against recommending approval and noted there was not enough data to gauge whether the drug was effective. While the FDA usually follows the recommendations of its advisory panels, the agency approved the drug under its accelerated approval pathway.

According to the Post, under the initial label, some 6 million people in the US with Alzheimer's disease may have been eligible for the treatment, which has a list price of $56,000 a year. NBC News previously reported that the drug could then cost the US government billions of dollars.

The new label now limits the drug to patients with early-stage disease, the Post says, noting that was the population in Biogen's trials. It estimates that the target patient population is now 1 million or 2 million.

According to CNN, Alfred Sandrock, the head of research and development at Biogen, says they submitted the new prescribing information in a bid to clarify the patient population studied in its trials.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.